254435-95-5
254435-95-5 性质
| 沸点 | 1294.2±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.011±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：≥100mg/mL（82.19mM） |
| 酸度系数(pKa) | 13.32±0.70(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
254435-95-5 用途与合成方法
DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication. Alisporivir (Debio-025) represents the prototype of a new class of non-immunosuppressive cyclophilin inhibitors. Alisporivir prevents HCV protein-mediated collapse of the respiration-driven mitochondrial membrane potential. Alisporivir prevents HCV protein-mediated mitochondrial dysfunction outside the context of apoptosis, calcium overload, production of ROS, dysfunction. In cell culture models, low-micromolar doses of alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with Alisporivir and ICN-1229 increases the anti-MERS-CoV activity in cell culture. Alisporivir pretreatment stimulates antigen presentation by hepatoma target cells, leading to enhancement of antigen-specific CD8+ T cell activation by 40%. Alisporivir induces an increase of MHC-I and beta-2 microglobulin on the surface of several cell lines.
Combination treatment with Alisporivir and ICN-1229 does not protect against SARS-CoV infection in a mouse model.
254435-95-5 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-12559 | 254435-95-5 | 254435-95-5 | 1mg | 1200 |
| 2024-11-08 | HY-12559 | 254435-95-5 | 254435-95-5 | 5mg | 3600 |
